The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The introduction of bevacizumab for the treatment of metastatic colorectal cancer (CRC) in Ontario and its effect on hepatic metastectomy.
William Robert Leeper
No relevant relationships to disclose
Hector Hugo Li Chang
No relevant relationships to disclose
Stephen Welch
Honoraria - Roche
David K Driman
No relevant relationships to disclose
Douglas Quan
No relevant relationships to disclose